UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

			
 	 	 	
Date of Report (Date of Earliest Event Reported):	 	September 1, 2016	
________________________
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________

				
Delaware	001-32335	 	88-0488686	
(State or other jurisdiction
of incorporation)	(Commission
File Number)	 	(IRS Employer
Identification No.)	

		
11388 Sorrento Valley Road, San Diego, California	92121	
(Address of principal executive offices)	(Zip Code)	

			
Registrant’s telephone number, including area code:	 	(858) 794-8889	
Not Applicable
(Former name or former address, if changed since last report)
  _________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

	

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)    On September 1, 2016, Halozyme Therapeutics, Inc. (the “Company”) announced that Mark J. Gergen has been appointed to serve as the Company’s Senior Vice President and Chief Operating Officer effective immediately.

From February 2013 until August 2016, Mr. Gergen, age 54, served as Executive Vice President and Chief Operating Officer at Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products. From May 2005 to November 2012, Mr. Gergen served in senior management positions, including most recently as Senior Vice President, Corporate Development, at Amylin Pharmaceutical, Inc., a biopharmaceutical company that was focused on the development and commercialization of medicines to treat chronic diseases. Mr. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in Business Administration from Minot State University.

There are no family relationships between Mr. Gergen and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Mr. Gergen does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.

Mr. Gergen will be paid an annual base salary of $435,000 and he will be eligible to participate in the Company’s executive officer incentive plans, with a 2016 bonus target equal to 45% of his prorated base salary. Upon joining the Company, Mr. Gergen received a stock option grant for 333,890 shares of common stock. The option grant will vest on the Company’s standard four year vesting schedule.

On September 1, 2016, the Company issued a press release announcing the appointment of Mr. Gergen as Senior Vice President and Chief Operating Officer. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

		
Exhibit No.	Description	
 	 	
99.1	Press release dated September 1, 2016	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

					
 	 	 	 	 	
 	 	HALOZYME THERAPEUTICS, INC.	
  	 	 	 	 	
September 1, 2016	 	By:	 	/s/ Harry J. Leonhardt	
 	 	Name:	 	Harry J. Leonhardt, Esq. 
	
 	 	Title:	 	Senior Vice President, General Counsel,
Chief Compliance Officer and Corporate Secretary	

EXHIBIT LIST

	

Exhibit No.	 	Description	
 	 	 	
99.1	 	Press release dated September 1, 2016	

Exhibit 99.1

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

Chris Burton
858-704-8352
ir@halozyme.com

    

HALOZYME NAMES MARK J. GERGEN AS
CHIEF OPERATING OFFICER

SAN DIEGO, Sept. 1, 2016 - Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer.

Gergen will be responsible for business development, including the management of Halozyme’s proprietary ENHANZE™ platform collaborations and overseeing the global product teams responsible for planning the development and commercialization of Halozyme’s oncology pipeline, including clinical operations and clinical collaborations.

“Mark brings a wealth of business development and operational experience that will be essential as we execute our plan to accelerate growth of the ENHANZE platform and develop and commercialize multiple oncology drugs,” said Dr. Torley. “With more than 20 years of healthcare and biotech experience, he will be a strong addition to our management team as we execute our growth strategy.”

Gergen joins Halozyme most recently from Mirati Therapeutics, an oncology biotech, where he was executive vice president and chief operating officer reporting to the CEO and responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions. He executed multiple successful partnerships, collaborations and licensing agreements.

Before Mirati, he spent 7 years at Amylin Pharmaceuticals as a member of the executive committee reporting to the CEO, where he led corporate development and alliances.

“I am excited to join the Halozyme team as the company continues to execute against its business objectives and corporate strategy,” said Gergen. “The advancements in the oncology pipeline together with the opportunity to grow the proprietary ENHANZE platform create a unique opportunity to build significant shareholder value.”

Prior to Amylin, Gergen held senior management roles for Cardionet and Advanced Tissue Sciences, as well as the large group purchasing organization, Premier, and medical device pioneer, Medtronic. He earned his B.A. in Business Administration from Minot State University in North Dakota and J.D. from the University of Minnesota Law School.

About Halozyme

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com .

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the Company's future expectations and plans for growth, future execution of the Company’s business strategy, the development and commercialization of product candidates and the potential benefits and attributes of such product candidates, future prospects of the Company’s ENHANZE platform and increasing the number of strategic partners) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results in executing the Company’s business strategy including its efforts to grow the ENHANZE platform, unexpected expenditures and costs, unexpected fluctuations or changes in revenues, including revenues from collaborators, unexpected results or delays in development of product candidates and regulatory review, regulatory approval requirements, the Company’s efforts to increase the number of strategic partners not producing expected results, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission.

####